GENETIC TECHNOLOGIES LIMITED (GTG)

The following ordinary fully paid deferred shares of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, due to the minimum subscription condition under the Non-Renounceable Entitlement Offer not having been meet: Security class code GTGN.

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately, following the release by GTG of an announcement regarding a breach of Chapter 10 of the Listing Rules.

The company provides an operational update on its blockchain activities. In relation to the framework agreement between BCG and GTG, to date, no shares have been issued under the framework agreement and no milestones specified have been achiebed. The share price of GTG needs to reach and remain at a minimum of 2.5c prior to any milestone shares being issued. Any rights to the 486,000,000 milestone shares upon achievement of milestones lapse between 27 December 2019 and 27 June 2020. Also, the Blockshine Health joint venture agreement was terminated on 6 August 2019. Regarding project Shivom which was signed on 2 March 2018, the parties have not progressed further with the undertakings contained in the agreement in recent times. GTG is yet to receive any formal requests for resources or further input or consideration into any blockchain based projects, whether that be via the previous Blockshine Health Joint Venture, BCG or from any other party. As such, GTG intends to remain focused on its core genetic testing business activities and are not currently considering any blockchain related projects. There is no present intention of the Board to change its composition.

ASX suspended the company for breach of Listing 10.1 and required the company to take corrective action. One form of corrective action was to cancel the transaction. The JV agreement has been terminated effective 6 August 2019. GTG did not receive any formal requests for resources or further input or consideration into any blockchain based projects via the Blockshine Health Joint Venture. As such, GTG has been very focused on its core genetic testing business activities this past calendar year and considers termination of the JV agreement will have no material adverse impact on company operations.

The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, pending an announcement regarding a breach of Chapter 10 of the Listing Rules.

The securities of Genetic Technologies Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

The company has entered into a non-binding terms sheet with Blockchain Global. In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share.

The company is presently in discussions with ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Global Ltd to explore the application of Blockchain technology to provide efficiencies and new opportunities leveraging off the GTG existing genomics business would result in a change of activities of GTG. While these discussions are continuing, the ASX has required that GTG continue in suspension.

The securities of Genetic Technologies Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately following the release of an announcement regarding restructuring plans and finalisation of funding. ASX Code: GTG

The securities of Genetic Technologies Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: GTG

securities reinstated

Genetic Technologies now expects that the capital raising will be finalised on 22 July 2011 (AEST), when a further announcement is expected to be made by the Company in compliance with the ASX listing rules, and at which time the Company expects to recommence trading on both the ASX and NASDAQ

securities suspended pending an announcement

Geoffrey Edgar Newing, 44, of Hawthorn East, Victoria, is sentenced to a total of 22 months imprisonment and was ordered to serve six months of this sentence before being released on a recognisance release order

former Genetic Technologies Limited (GTG) chief operating officer, Geoffrey Edgar Newing, today pleaded guilty to five counts of market manipulation in the Melbourne Magistrates' Court, following an investigation by ASIC - the charges relate to Mr Newing's involvement in the trading of GTG shares between 16 May 2006 and 7 August 2006 - ASIC alleges that during this period Mr Newing took part in transactions involving purchases of more than 2,500,000 GTG shares through a share trading account held in the name of his related company, Palamine Pty Ltd. These transactions, according to ASIC, were likely to create or maintain an artificial price for trading in GTG shares

name changed from Duketon Goldfields Limited